Point of Care

Rapid, decentralised testing at the bedside, clinic and field, including immunoassays and portable molecular platforms.

Latest

Point of Care

Respiratory virus testing shows limited impact on antibiotic prescribing in primary care

Journal of primary health care August 25, 2026

Significance 3/10 Point of Care

Triplex RPA assay enables rapid, sensitive detection of three bovine pathogens

Sheng wu gong cheng xue bao = Chinese journal of biotechnology August 25, 2026

Significance 4/10 Point of Care

Paper-based POC platform enables rapid whole-blood PT/INR and haematocrit monitoring with AI classification

Lab on a chip August 25, 2026

Significance 7/10 Point of Care

Dried blood spot screening for congenital hypothyroidism supports newborn screening expansion in Pakistan

Endocrinology, diabetes & metabolism September 1, 2026

Significance 7/10 Point of Care

Adapting trauma guidelines and point-of-care diagnostics improves LMIC polytrauma outcomes

World journal of methodology September 20, 2026

Significance 6/10 Point of Care

Integrated rapid diagnostics and AI prediction accelerate targeted antibiotic therapy in a resource-limited setting

PloS one August 20, 2026

Significance 7/10 Point of Care

Decentralized POC HCV testing achieves over 90% uptake in LMICs

Liver international : official journal of the International Association for the Study of the Liver September 1, 2026

Significance 7/10 Point of Care

Mechanically automated paper-based CRISPR/RPA platform enables instrument-free Vibrio vulnificus detection

ACS sensors August 14, 2026

Significance 6/10 Point of Care

CRISPR-Cas12a hydrogel microarray enables multiplex adenovirus detection with qPCR concordance

ACS infectious diseases August 14, 2026

Significance 5/10 Point of Care

CRISPR RNA engineering strategies enhance single-nucleotide discrimination in nucleic acid diagnostics

Angewandte Chemie (International ed. in English) August 14, 2026

Significance 5/10 Point of Care

BV Rapid Blue demonstrates high sensitivity and NPV for bacterial vaginosis screening in pregnancy

PloS one August 14, 2026

Significance 6/10 Point of Care

Point-of-care multiplex PCR reduces isolation costs for non-infected HCID suspects in economic model

Infection August 14, 2026

Significance 5/10

Landmark studies

Point of Care

155 studies

NEJM: CRISPR-Cas9 Gene Editing Achieves 92% Sustained TTR Reduction in Hereditary Amyloidosis The New England journal of medicine 2025 Landmark-class JAMA Meta-Analysis: SGLT2 Inhibitors Reduce Kidney Progression and Death Regardless of Diabetes or Albuminuria JAMA 2026 Landmark-class SGLT2 Inhibitors Protect Kidneys Regardless of Baseline GFR or Albuminuria in 70,000-Patient Meta-Analysis JAMA 2026 Landmark-class CRISPR Gene Editing of ANGPTL3 Achieves Up to 80% Lipid Target Reduction in Phase 1 Cardiovascular Trial The New England journal of medicine 2025 Landmark-class Lancet RCT: CRP Point-of-Care Decision Tool Safely Cuts Pediatric Antibiotic Prescribing by 28% Lancet (London, England) 2025 Landmark-class Acalabrutinib-Obinutuzumab Delivers Durable Survival Benefit in Treatment-Naive CLL at 6-Year Follow-Up Blood 2025 Landmark-class CRISPR-Engineered Allogeneic CAR-T Cells Induce Remission in Refractory Lupus Nature medicine 2025 Landmark-class Lancet ENERGIZE Trial: Mitapivat Raises Haemoglobin in Non-Transfusion-Dependent Thalassaemia Lancet (London, England) 2025 Landmark-class Phase 2 Trial Confirms CRISPR-Based NTLA-2002 Reduces Hereditary Angioedema Attacks by 75-77% vs Placebo The New England journal of medicine 2024 Landmark-class BRILLIANCE Trial: In Vivo CRISPR Gene Editing Improves Vision in Inherited Retinal Degeneration The New England journal of medicine 2024 Landmark-class Lancet Oncology: Largest CMMRD Cohort Reveals 90% Cancer Incidence by Age 18 and Gene-Specific Outcomes The Lancet. Oncology 2024 Landmark-class Single-Dose In Vivo CRISPR Editing of KLKB1 Reduces Angioedema Attacks by Up to 97% in Phase 1 Trial The New England journal of medicine 2024 Landmark-class Five-Year ZUMA-1 Follow-Up: 43% of Refractory Lymphoma Patients Alive After Axi-cel CAR T Therapy Blood 2023 Landmark-class Large Individual Patient Data Analysis Quantifies the Prognostic Cost of p16/HPV Discordance in Oropharyngeal Cancer The Lancet. Oncology 2023 Landmark-class Non-Viral CRISPR-Edited Neoantigen-Specific T Cells Traffic to Tumours in First-in-Human Solid Cancer Trial Nature 2022 Landmark-class POC Nucleic Acid Testing Dramatically Accelerates HIV Treatment in Infants Lancet (London, England) 2022 Landmark-class NEJM Trial: Decentralised On-Site Molecular TB Testing Increases Diagnosis and Same-Day Treatment The New England journal of medicine 2021 Landmark-class Cilta-cel CAR T-Cell Therapy Achieves 97% Response Rate in Heavily Pretreated Multiple Myeloma Lancet (London, England) 2021 Landmark-class First-in-Human Trial of Multiplex CRISPR-Cas9 Edited T Cells Shows Safety and Durable Engraftment in Cancer Science (New York, N.Y.) 2020 Landmark-class NEJM PACE Trial: CRP Point-of-Care Testing Safely Cuts Antibiotic Prescribing in COPD Exacerbations The New England journal of medicine 2019 Landmark-class CRISPR-Cas Systems: From Genome Editing to Programmable Diagnostics Science (New York, N.Y.) 2018 Landmark-class IFCC Framework for Implementing High-Sensitivity Cardiac Troponin Point-of-Care Testing in Acute Care Settings Clinical chemistry and laboratory medicine 2026 Landmark-class Obicetrapib Lowers LDL-C by 36% in Familial Hypercholesterolaemia: BROOKLYN Trial Results Nature medicine 2026 Landmark-class CASTLE Basket Trial: CD19 CAR-T Achieves Remission Across Three Autoimmune Diseases Nature medicine 2026 Landmark-class Permethrin-Treated Baby Wraps Cut Childhood Malaria Incidence by 66% in Ugandan RCT The New England journal of medicine 2025 Landmark-class

Show all 155 studies